EcoDrugPlus

Proteasome Subunit Alpha Type-2-Like

Ensembl ID : ENSOKIG00005025856
Gene Symbol: LOC109884237
2 Cross references
202 Possible Orthologues:

Proteasome Subunit Alpha Type-2-Like

Ensembl ID : ENSOKIG00005005805
Gene Symbol: LOC109903426
2 Cross references
205 Possible Orthologues:

Proteasome Subunit Alpha Type-2-Like

Ensembl ID : ENSOKIG00005026099
Gene Symbol: LOC109884242
2 Cross references
203 Possible Orthologues:

Proteasome Subunit Alpha Type-4

Ensembl ID : ENSOKIG00005047669
Gene Symbol: LOC109866941
3 Cross references
166 Possible Orthologues:

Proteasome Subunit Alpha Type-6-Like

Ensembl ID : ENSOKIG00005017010
Gene Symbol: LOC109900592
3 Cross references
261 Possible Orthologues:

Proteasome Subunit Alpha Type-7

Ensembl ID : ENSOKIG00005033272
Gene Symbol: LOC109902778
3 Cross references
130 Possible Orthologues:

Proteasome Subunit Alpha Type-7-Like

Ensembl ID : ENSOKIG00005019024
Gene Symbol: LOC109898083
2 Cross references
131 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSOKIG00005050787
Gene Symbol: PSMB11
1 Cross references
164 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSOKIG00005039888
Gene Symbol: PSMB11
1 Cross references
163 Possible Orthologues:

Proteasome Subunit Beta Type-1-B

Ensembl ID : ENSOKIG00005048106
Gene Symbol: LOC116376158
3 Cross references
211 Possible Orthologues:

Proteasome Subunit Beta Type-2-Like

Ensembl ID : ENSOKIG00005015590
Gene Symbol: LOC109903688
3 Cross references
214 Possible Orthologues:

Proteasome Subunit Beta Type-3

Ensembl ID : ENSOKIG00005032720
Gene Symbol: LOC109865743
3 Cross references
253 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).